

## Freedom of Information Request

Ref: 22-732

4 January 2023

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

### Question 1

|  |                                      |    |
|--|--------------------------------------|----|
| <b>Does University Hospitals Bristol and Weston NHS Foundation Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?</b><br>We have individual chemotherapy protocols for each of the SACT regimes that we use (see below) but do not have an overarching guideline / pathway. We follow NICE / ESMO guidelines | Yes                                  | No |
|  | <i>If Yes please provide a copy.</i> |    |

### Question 2

| Does University Hospitals Bristol and Weston NHS Foundation Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer? |                                     |    |
|---|-------------------------------------|----|
| Sotorasib (Lumykras)  | Yes                                 |    |
|   | <i>If yes please see question 3</i> |    |
| Entrectinib (Rozlytrek)   |                                     | No |
| Larotrectinib (Vitrakvi)  |                                     | No |
| Dabrafenib (Tafinlar)   |                                     | No |
| Trametinib (Mekinist)   |                                     | No |
| Capmatinib (Tabrecta)   |                                     | No |
| Tepotinib (Tepmetko)  | Yes                                 |    |
| Bevacizumab (Avastin)   | Yes                                 |    |
| Ramucirumab (Cyramza)   |                                     | No |
| Atezolizumab (Tecentriq)  | Yes                                 |    |
| Durvalumab (Imfinzi)  | Yes                                 |    |
| Cemiplimab (Libtayo)  |                                     | No |
| Nivolumab (Opdivo)  | Yes                                 |    |

|                                  |     |    |
|----------------------------------|-----|----|
| Pembrolizumab (Keytruda)         | Yes |    |
| Ipilimumab (Yervoy)              |     | No |
| Afatinib (Giotrif)               | Yes |    |
| Dacomitinib (Vizimpro)           |     | No |
| Erlotinib (Tarceva)              | Yes |    |
| Gefitinib (Iressa)               | Yes |    |
| Osimertinib (Tagrisso)           | Yes |    |
| Amivantamab (Rybrevant)          |     | No |
| Mobocertinib (Exkivity)          |     | No |
| trastuzumab deruxtecan (Enhertu) |     | No |
| Alectinib (Alecensa)             | Yes |    |
| Brigatinib (Alunbrig)            | Yes |    |
| Ceritinib (Zykadia)              | Yes |    |
| Crizotinib (Xalkori)             | Yes |    |
| Lorlatinib (Lorviqua )           | Yes |    |
| Entrectinib (Rozlytrek)          |     | No |
| Pralsetinib (Gavreto)            |     | No |
| Selpercatinib (Retsevmo)         | Yes |    |
| Nintedanib (Vargatef®)           | Yes |    |

All protocols are available at Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance

[Protocols Archive - SWAG Cancer Alliance](#)

#### Question 3

**If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?**

There is open access at [Protocols Archive - SWAG Cancer Alliance](#)

#### Question 4

|  |                                     |    |
|--|-------------------------------------|----|
| <b>Does University Hospitals Bristol and Weston NHS Foundation Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?</b> | Yes                                 | No |
|  | <i>If yes please provide a copy</i> |    |
| No.  |                                     |    |

#### Question 5

**Is University Hospitals Bristol and Weston NHS Foundation Trust part of a Cancer alliance or network, if so which ones?**

The Trust is part of the Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer  
University Hospitals Bristol and Weston NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

#### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**